What will be left is an industry dominated by behemoths, raising questions about the fates of smaller drug companies, as well as the countless small biotechs hungry for suitors.

• 经过这波整合，制药行业将出现少数超级巨头把持的局面，中小制药企业以及数不清的急切希望被收购的小型生物技术公司的命运成了问题。